Phase I trial shows positive results for stem cell treatment in patients with major cornea injuries

A team led by researchers from Mass Eye and Ear, a member of Mass General Brigham, reports the results of a phase I trial of a revolutionary stem cell treatment called cultivated autologous limbal epithelial cell transplantation (CALEC), which was found to be safe and well-tolerated over the short term in four patients with significant chemical burns in one eye.

Why Novartis is changing the name of its research labs

Swiss drugmaker Novartis’ research and development hub has a new name — and a new guiding strategy. The hub, which is headquartered in Cambridge, Mass.,

September 8, 2023

Cell manufacturing company raises $19M Series A to increase capacity, staff numbers

A London-based startup that builds machines that convert stem cells into more specific cell types has closed a $19 million Series A round to boost

December 1, 2023

More regulation could be coming for drug ads

WASHINGTON — Government regulators may soon decide whether to crack down on distracting visuals in television drug commercials or require subtitles about side effects, a

August 8, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.